NCT03375021 is a Phase 2 clinical trial of CX717 200 mg in Attention Deficit Hyperactivity Disorder, sponsored by RespireRx.

Who is sponsoring NCT03375021?

NCT03375021 is sponsored by RespireRx.

What drugs are being tested in NCT03375021?

Interventions in NCT03375021: CX717 200 mg, CX717 800 mg, Placebo.

What condition does NCT03375021 study?

NCT03375021 studies Attention Deficit Hyperactivity Disorder.

Is NCT03375021 still recruiting?

NCT03375021 is currently completed. Last updated 15 December 2017.

Last reviewed 2017-12-15 · How we verify

NCT03375021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CX717 in the Treatment of Adult ADHD

Completed Phase 2 Last updated 15 December 2017

What this trial tests

Phase 2 trial testing CX717 200 mg in Attention Deficit Hyperactivity Disorder in 68 participants. Completed in 10 January 2006.

Timeline

19 July 2005

Primary endpoint
10 January 2006

10 January 2006

Quick facts

Lead sponsor	RespireRx
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	68
Start date	19 July 2005
Primary completion	10 January 2006
Estimated completion	10 January 2006

Drugs / interventions tested

CX717 200 mg — full drug profile →
CX717 800 mg — full drug profile →
Placebo

Conditions studied

Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

RespireRx — full company profile →

Who can join

Adults 18 to 50, male only, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.
Kadriu B, Musazzi L, Johnston JN, Kalynchuk LE, et al · · 2021 · cited 37× · PMID 34358693 · DOI 10.1016/j.drudis.2021.07.027
Positive AMPA and Kainate Receptor Modulators and Their Therapeutic Potential in CNS Diseases: A Comprehensive Review.
Vialko A, Chałupnik P, Szymańska E. · · 2025 · cited 1× · PMID 40650226 · DOI 10.3390/ijms26136450
Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today.
Radin DP, Lippa A, Rana S, Fuller DD, et al · · 2025 · cited 1× · PMID 39894310 · DOI 10.1016/j.pbb.2025.173967

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder

Currently open trials in the same condition.

NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03375021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RespireRx
Last refreshed: 15 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03375021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing